Savior LLC’s ImmunityBio IBRX Stock Holding History

Savior LLC’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-92	Closed	-$1K	–	467
2021 Q2	$1K	Hold	92	–	–	﹤0.01%	798
2021 Q1	$2K	Sell	92 -1	-1%	-$26	﹤0.01%	749
2020 Q4	$1K	Sell	93 -1	-1%	-$10	﹤0.01%	792
2020 Q3	$1K	Hold	94	–	–	﹤0.01%	765
2020 Q2	$1K	Buy	+94	New	+$531	﹤0.01%	738

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Savior LLC's IBRX Position: Q3 2021 in Review

Savior LLC sold out of ImmunityBio (IBRX) in Q3 2021, closing a stake of 92 shares — an estimated $1K sold.

Savior LLC first reported a position in IBRX in Q2 2020 and held it in 5 quarters. The position peaked at $2K in Q1 2021. 126 funds tracked by Wall St. Rank hold IBRX as of Q3 2021.

Savior LLC reported no remaining ImmunityBio position as of Q3 2021 after selling out during the quarter.
Savior LLC sold 92 ImmunityBio shares in Q3 2021, an estimated $1K.
Savior LLC first reported a position in ImmunityBio in Q2 2020 and held it in 5 quarters.
Savior LLC's ImmunityBio position peaked at $2K in Q1 2021.
126 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2021.

Based on Savior LLC's 13F filing for Q3 2021, filed 5 Oct 2021.